Medicine News and Research

RSS

Phase II study: Fostamatinib improves outcomes in RA patients

AstraZeneca's new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to ongoing treatment with methotrexate, according to phase II study data published in The New England Journal of Medicine today.

23 Sep 2010

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.

23 Sep 2010

Doctors misuse antibiotics to treat patients with respiratory tract infections: Study

Doctors frequently misuse antibiotics when treating patients hospitalized with respiratory tract infections (RTIs), according to a study to be published in the November issue of Infection Control and Hospital Epidemiology.

23 Sep 2010

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, today announced that the Company will be presenting its Autologous Adult Stem Cell VSEL Technology for the Treatment of Battlefield Wounds at The USU-HJF Military Medicine Symposium in Washington DC, September 23rd, 2010.

23 Sep 2010

New analytical technique to improve personalized medicine

In the future, even before the start of the treatment, physicians will be able to establish how patient's blood binds a given medicine and what doze should be applied in order to obtain the concentration in the body that would be optimal for the treatment. A new simple method of analysis of chemical reactions proceeding in solutions has been developed in the Institute of Physical Chemistry of the Polish Academy of Sciences.

23 Sep 2010

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells.

23 Sep 2010

Merck expands patient assistance programs to provide medicines to needy people

Today, Merck announced that it has significantly expanded the number of Merck medicines available through its Merck Helps patient assistance programs, which include the Merck Patient Assistance Program, the Merck Vaccine Patient Assistance Program, the ACT Program for Oncology and Hepatitis C medicines, and the SUPPORT Program for HIV/AIDS medicines.

23 Sep 2010

Scientists identify genetic variants that increase asthma susceptibility

An international study looking at DNA from over 26,000 people has identified several genetic variants that substantially increase susceptibility to asthma in the population. The findings, published in the New England Journal of Medicine, will help scientists to focus their efforts to develop better therapies for the illness.

23 Sep 2010

Portable laser devices to probe early signs of diseases

Portable devices that use a laser beam to probe bones, teeth, and other parts of the body for early signs of diseases like osteoporosis and tooth decay may seem like something out of science fiction. But those devices are moving closer to reality, according to an article in the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.

23 Sep 2010

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

"The U.N. estimates that diarrheal diseases kill 1.8 million people every year. … So you might take it as good news that American company Ventria Bioscience says it has hit on an improvement to existing rehydration therapies, which could mean another tool in the fight against diarrhea," according to a Wall Street Journal editorial examining the delays the company has experienced since it first sought to have its product approved by the FDA back in 2004, even "[a]fter a panel of food, medicine, immunology, child nutrition and health experts had declared its product safe."

23 Sep 2010

Aeras Global TB Vaccine Foundation to initiate clinical trial of new investigational vaccine

At an international gathering of TB vaccine researchers in Tallinn today, the Aeras Global TB Vaccine Foundation announced it will initiate a clinical trial of an investigational live recombinant tuberculosis vaccine to be led by researchers at Saint Louis University in St. Louis, Missouri, USA. The announcement was made at the Second Global Forum on TB Vaccine Development.

23 Sep 2010

Scientists develop humanized mouse model to study typhoid fever

Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.

23 Sep 2010

Researchers develop drug to eliminate disease transmission by cough

What if there was a drug that could completely eliminate airborne disease transmission that occurs when someone coughs. Researchers at the University of Alberta believe they have found a way to achieve this.

23 Sep 2010

Northwestern Medicine participates in world's first human embryonic stem cell clinical trial for spinal cord injury

Northwestern Medicine is the first site open for enrollment in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury. Following the procedure, participants will receive rehabilitation treatment at The Rehabilitation Institute of Chicago (RIC).

23 Sep 2010

Women face sexual function problems after breast cancer

A new study published in the Journal of Sexual Medicine looked at whether women were more likely to experience sexual problems after breast cancer. The results showed that 70% of women were facing sexual function problems approximately two years post diagnosis.

23 Sep 2010

Study may help develop preventative treatments for womb infections

Researchers funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have established in mice the mechanism that detects and responds to the presence of bacteria in the womb a discovery that opens up the possibility of new preventative treatments for diseases like pelvic inflammatory disease and Chlamydia.

23 Sep 2010

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Infinity Pharmaceuticals, Inc. today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented during the 35th Congress of the European Society of Molecular Oncology (ESMO), in Milan, Italy.

23 Sep 2010

Beta-Pro donates human pancreatic islet cells to diabetes researcher

The cellular services company Beta-Pro LLC, announced today that it donated more than 300,000 human pancreatic islet cells to nationally renowned diabetes researcher Raghavendra G. Mirmira, M.D., Ph.D., the Eli Lilly & Co. Professor of Pediatric Diabetes, Indiana University School of Medicine, Herman B.

23 Sep 2010

Anthera Pharmaceuticals closes financing transaction

Anthera Pharmaceuticals, Inc., today announced that it has entered into definitive agreements with certain accredited investors in connection with a private placement, or PIPE, financing transaction pursuant to Section 4(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder.

23 Sep 2010

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

New Phase III data found that investigational linagliptin therapy resulted in significant reductions in blood sugar as measured by hemoglobin A1c (HbA1c) when compared to placebo, both when added to sulfonylurea (SU) in inadequately controlled type 2 diabetes (T2D) patients, and when administered as monotherapy in T2D patients for whom metformin is inappropriate.

22 Sep 2010

Medicine News and Research

Phase II study: Fostamatinib improves outcomes in RA patients

Implantation of new bioprosthetic-tissue valve in patients with severe aortic stenosis saves lives

Doctors misuse antibiotics to treat patients with respiratory tract infections: Study

NeoStem to present VSEL Technology for Battlefield Wounds treatment at USU-HJF Symposium

New analytical technique to improve personalized medicine

Signal Genetics, Array BioPharma partner to advance personalized medicine in multiple myeloma

Merck expands patient assistance programs to provide medicines to needy people

Scientists identify genetic variants that increase asthma susceptibility

Portable laser devices to probe early signs of diseases

Opinions: Genetically-modified crops can improve vaccines; MDG focus on women and girls; U.S. leadership for MDGs; Boosting access to drugs; Merits of bilateral development assistance

Aeras Global TB Vaccine Foundation to initiate clinical trial of new investigational vaccine

Scientists develop humanized mouse model to study typhoid fever

Researchers develop drug to eliminate disease transmission by cough

Northwestern Medicine participates in world's first human embryonic stem cell clinical trial for spinal cord injury

Women face sexual function problems after breast cancer

Study may help develop preventative treatments for womb infections

Infinity Pharmaceuticals to present IPI-926 inhibitor Phase 1 data at ESMO Congress

Beta-Pro donates human pancreatic islet cells to diabetes researcher

Anthera Pharmaceuticals closes financing transaction

Boehringer Ingelheim to present linagliptin Phase III data at 46th EASD

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News